Latest results FY2026 · Prices updated Oct 30, 2026
HQ: Tokyo, TokyoFounded 1939696 employeesWebsite
A manufacturer of in vitro diagnostic reagents and clinical testing equipment. It has developed distinctive technologies for areas including fecal occult blood and infectious disease testing.
Business segments (share of revenue)
Latest results
FY2026
vs. same period a year earlier
Company forecastFY2027
| Segment | Share | Revenue | Operating profit | Margin |
|---|---|---|---|---|
| Diagnostic Reagents Business | 100% | ¥41.9B | ¥2.9B | 7.0% |
Close (Oct 30, 2026)
¥2,307-0.9% (1Y)
Eiken -0.9% over 1Y, 8.6pt below the industry average (9 companies, +7.7%).
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Updated Oct 30, 2026.
| Period | Revenue | Op. profit | Net income | Total assets | Revenue YoY |
|---|---|---|---|---|---|
| 2026FY | ¥41.9B | ¥2.9B | ¥3.7B | ¥62.7B | — |
Sources: annual securities reports, earnings releases and other public disclosures (Jan 2026)
Data may contain input errors. For reference only; we accept no responsibility for its accuracy.
